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Abstract 36 
This summary report for the “in vivo predictive dissolution and simulation workshop” 37 
highlights presentations from a two-day workshop held on September 11-12, 2017.  This 38 
workshop was aimed to present scientists at FDA, EMA, industry and academia the most 39 
recent advances in dissolution methodologies and scientific knowledge for oral drug 40 
products, which could be useful for guiding early phase development, bioavailability (BA) 41 
and bioequivalence (BE) studies and Scale-Up and Post-Approval Changes (SUPAC) of 42 
oral products.  Presentations and discussions focused on appropriate in vitro and in silico 43 
applications and tool selections to predict in vivo bioperformance of oral formulations.  44 
Product developability and Quality by Design (QbD) would be determined by the 45 
physicochemical characteristics of active pharmaceutical ingredients (API), in vitro 46 
dissolution and in silico models/computer simulation.  Many methodologies and 47 
applications are available to predict in vivo bioperformance of oral products/formulations.  48 
It is crucial that the selections of appropriate tools based on API and formulations to 49 
maximize in vivo prediction by in vitro/in silico results.  This workshop presented cutting-50 
edge tools/methodologies and how to select the right tools from a methodology toolbox and 51 
testing parameters to predict best in vivo bioperformance of test products.  The 52 
combinations of in vivo minded in vitro dissolution methodologies and computational 53 
approaches become mainstream to predict oral absorption/plasma profiles of oral products.  54 
This workshop provides the degree of advancement within state-of-the-art scientific 55 
knowledge, validation, and development and the extent to which the regulatory community 56 
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has absorbed and accepted these advancements in science-based mechanistic approaches to 57 
oral drug product development. 58 
Introduction 59 
A two-day workshop entitled “In Vivo Predictive Dissolution and Simulation” was held 60 
September 11-12, 2017 in Washington DC focused on the selection of applications, 61 
methodologies, and scientific advancements to predict in vivo bioperformance of oral drug 62 
products/oral drug formulations based on the active pharmaceutical ingredient (API) and 63 
drg product formulation.  This workshop was fully sponsored by the AAPS and featured 64 
speakers from industry, academia, and regulatory agencies to introduce the state-of-the-art 65 
in cutting-edge applications, methodologies and latest initiatives in in vivo prediction of 66 
oral drug product performance to attendees worldwide.  A broad range of dissolution 67 
methodologies and simulations together with the determination of developability based on 68 
physicochemical characteristics were discussed specific considerations for in vivo 69 
prediction implementing bioavailability (BA), bioequivalence (BE), and quality by design 70 
(QbD), in this two-day workshop.   71 
The objectives of this workshop were to: 72 
● Present scientists at regulatory agencies, industry and academia the most recent 73 
advances in dissolution methodologies, computational applications and science for 74 
oral drug products to predict in vivo behavior of oral drug products, which could be 75 
useful for guiding early phase development, bioavailability (BA) and 76 
bioequivalence (BE) studies and Scale-Up and Post-Approval Changes (SUPAC) 77 
of oral products.  78 
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● Present state-of-the-art in vivo predictive dissolution methodologies for drug 79 
products, including determination in vitro testing parameters to achieve in vivo 80 
predictive and desired outcomes, and how to interpret in vitro results and 81 
translating them into potential IVIVCs.  82 
● Present state-of-the-art scientific analysis and knowledge using the latest 83 
mechanistic BCS-subclass-based in vivo and in silico predictive dissolution 84 
methodologies.  85 
● Present a mechanistic basis for more efficiently reviewing pharmaceutical product 86 
change applications and new generic product applications, including BE studies, 87 
assuring therapeutic benefits and safety of oral drug products for public health.  88 
● Provide a forum to discuss in vitro dissolution and in silico simulation through 89 
case studies.   90 
Workshop participants learned the newest mechanistic, BCS Subclass based, in vivo 91 
predictive dissolution methodologies and physiologically-based computer simulation and 92 
science, and were presented with discussion on state-of-the-art dissolution methodologies 93 
based on physicochemical characteristics of API. Case studies were presented where 94 
current quality control (QC) dissolution methodologies have been inadequate predicting in 95 
vivo performance, and bioequivalence failure.  An in vivo predictive dissolution could 96 
provide mechanistic explanation of in vivo results which could help guide an early 97 
formulation development effort, bridge scale up work and understand reference product 98 
profiles for generic formulation development. 99 
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This workshop was targeted to regulatory scientists, pre-formulation, formulation, 100 
biopharmaceutics, and QC scientists in industry, and graduate students and scientists in the 101 
academia. The workshop focused on presenting the most recent methods and scientific 102 
understanding related to possible pharmacokinetic performance and bioequivalence (BE) 103 
risk, in vivo dissolution/prediction for a test formulation/a test oral product to meet for 104 
ensuring the therapeutic efficacy of modified/changed product.  Formulation changes occur 105 
frequently over the course of an innovator product’s lifetime due to composition, 106 
manufacturing, and site of manufacturing changes.  BE provides an important standard for 107 
the development and approval of multi-source and generic drug products, the most rapidly 108 
expanding segment of the pharmaceutical industry worldwide.  The workshop benefited the 109 
audience by presenting the mechanistic basis for more efficiently designing pharmaceutical 110 
product/formulation and for quality by design (QbD) studies. 111 
  112 
Day 1 113 
In vivo buffers and buffer properties for affecting solubility and dissolution rate. 114 
Dr. Gregory E. Amidon (University of Michigan) led off the conference making the case 115 
that the critical link between oral solid dosage form formulation, in vivo plasma levels, and 116 
therapeutic effect is in vivo dissolution.  He discussed several key aspects important to the 117 
development of relevant in vitro methods focusing on our improved understanding of 118 
bicarbonate as our primary lumenal buffer.  Accurate prediction of dissolution rate requires 119 
an understanding of the conditions at the dissolving drug surface (1, 2). For acidic or basic 120 
drugs, an in vitro measurement of dissolution that reflects in vivo conditions requires 121 
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dissolution media that yields a surface pH (pH0) representative of in vivo conditions (1-6).  122 
The improved understanding of bicarbonate as a buffer is important and confirms that 123 
lumenal bicarbonate buffer concentration and buffer capacity is very low and this is 124 
critically important to developing methodologies that reflect in vivo pH0 (7).  This more 125 
comprehensive understanding of in vivo hydrodynamic and chemical conditions will allow 126 
for physiologically and physicochemically relevant in vitro dissolution testing to be 127 
performed on a sound, scientific basis.   128 
In Vivo Gastrointestinal Fluid Composition and Effects of Drug Substance 129 
Physiochemical Properties on Solubilization 130 
Dr. Christel Bergström (Uppsala University) continued with a thorough presentation of 131 
composition of human intestinal fluids. She emphasized that recent clinical studies pointed 132 
at a higher pH in the stomach than that typically used in compendial media (median of 2.5 133 
with a range of 1.7-3.3 in comparison to compendial pH of 1.0-1.2), a lower buffer capacity 134 
in the upper gastrointestinal tract than previously thought, and a larger intra- and inter-135 
individual variability in bile salts and phospholipids than previously has been reported (7-136 
9). These factors may significantly affect both dissolution rate and solubilization in the 137 
human intestinal tract. For this reason, there is not a single biorelevant medium that can be 138 
used to provide insights into the expected variability of dissolution rate and solubilization; 139 
rather a number of biorelevant media is likely to be needed to provide insights into the 140 
expected variability in vivo. She then linked the performance of drugs to their 141 
physicochemical properties and in particular pointed at the usefulness of understanding the 142 
role of lipophilicity, solid state properties and extent of ionization on the dissolution in 143 
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human intestinal fluids (10, 11). These physicochemical properties will inform on which 144 
types of biorelevant media to select for a particular compound. Further, computational 145 
modeling was discussed and identified as a tool that merits to be used to predict e.g. 146 
dissolution, solubility and biopharmaceutical performance (12). She identified that more 147 
clinical data on the impact of the fed state on drug dissolution are warranted to better 148 
understand inter-individual variability in the fed state. 149 
Impacts of In Vivo Fluid Hydrodynamics on Dissolution and Absorption in the 150 
Human Intestines 151 
Dr. James G. Brasseur (University of Colorado) discussed the impacts of intestinal fluid 152 
motions (“hydrodynamics”) on the processes by which drug molecules are released from 153 
clouds of small drug particles from a disintegrated tablet or capsule as particles and 154 
molecular concentrations are transported within the intestinal lumen and drug molecules are 155 
absorbed at the mucosal surface. Emphasis was placed on the varying impacts of different 156 
classes of motility patterns (i.e., changes in luminal geometry along gut segments as a 157 
function of time driven by contraction of the muscle fibers within the intestinal wall) 158 
associated with the different migrating motor complex (MMC) phases of contraction when 159 
the gut is in the fasting state vs. fed state motility. Whereas peristaltic motility in the fasting 160 
state drives the transport of residual material from the gut, the dominant function in the fed 161 
state is nutrient absorption, associated with segmental motions that locally mix intestinal 162 
liquid content in addition to bulk transport by peristalsis. The rate of release of drug 163 
molecules from drug particles (dissolution) is modulated by flow patterns that transport 164 
thousands of drug particles preferentially within localized regions and by the hydrodynamic 165 
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enhancement in the rate of release of molecules from the surface of individual drug 166 
particles from flow field characteristics local to the moving particle. Dr. Brasseur described 167 
the mathematical framework for single particle dissolution rate and showed that the 168 
hydrodynamic enhancement of particle dissolution rate was represented within a 169 
normalized molecular flux, historically referred to as the “Sherwood number.”. It was 170 
shown that this normalized particle flux is at the core of mathematical model formulations 171 
for dissolution from clouds of drug particles.  Dr. Brasseur then went into a detailed review 172 
of recent research into two key hydrodynamic influences on particle dissolution rate (i.e., 173 
normalized flux): (1) the convection effect which arises from “slip” velocity between the 174 
moving particle and the surrounding fluid, and (2) a “shear-rate” effect that has been 175 
recently discovered, quantified and experimentally validated that arises from drug particle 176 
spin induced by hydrodynamic shear-rate at the location of the particle. Using a 177 
computational fluid dynamics in vivo simulation environment in which the particle 178 
dissolution model was embedded, Dr. Brasseur showed that the hydrodynamic shear-rate 179 
effect creates major enhancements in drug dissolution while the convection effect provides 180 
only a minor influence due to the small size of the particles. Additional discussion was 181 
presented of the physical processes underlying the balance between release and absorption 182 
of ibuprofen in vivo in the presence of peristaltic motility and high permeability. This 183 
balance involves the interplay between diffusion and hydrodynamic transport of drug from 184 
the bulk to the mucosal surface and is strongly impacted by the size (or volume) of the 185 
pocket of intestinal liquid in which drug molecules are released and transported. 186 
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Dissolution Methodologies and Selection of Study Conditions Based upon Drug 187 
Physicochemical Characteristics (BCS subclass) & Dosage Forms 188 
Dr. Deanna Mudie (Lonza Pharma & Biotech) presented a mechanistic approach for 189 
selecting in vitro dissolution methodologies and testing parameters for designing oral drug 190 
product formulations and differentiating them with respect to bioperformance. This 191 
approach relies upon first predicting the rate determining steps to in vivo absorption based 192 
upon the drug substance and product of interest, and an understanding of the complex and 193 
heterogeneous gastrointestinal tract. For example, dimensionless numbers (e.g. Do, Dn & 194 
Pn) can be used to predict whether a compound may be solubility-permeability, 195 
permeability or dissolution rate limited in vivo (13, 14). BCS sub-classification can be used 196 
together with knowledge of the drug product formulation as a basis for predicting relative 197 
extent of gastric to intestinal dissolution (15). To demonstrate this methodology, Dr. Mudie 198 
presented a case study of spray-dried amorphous solid dispersions of itraconazole with 199 
hydroxypropyl methylcellulose acetate succinate dosed to rats (16). Using a material 200 
sparing membrane flux apparatus (17), colleagues at Lonza Pharma & Biotech were able to 201 
show that the maximum absorption rate for each formulation rank ordered with membrane 202 
flux in vitro when the test was set up to be solubility-permeability limited and a biorelevant 203 
fluid composition representative of fast rats was selected.                                                                                                                                                                                    204 
Direct Measurement of In Vivo Dissolution of IR and MR Drug Products in Human 205 
GI Tract 206 
Dr. Duxin Sun (University of Michigan) presented the in vitro/in vivo data analysis of a 207 
human intubation study and the challenge of in vivo-in vitro correlation (IVIVC) for the 208 
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local acting drugs with the administration of modified release (MR) mesalamine oral 209 
formulations, Pentasa, Apriso, and Lialda, along with oral mesalamine solution and an 210 
immediate release (IR) ibuprofen formulation. The specialized catheter with 4 aspiration 211 
channels allowed the measurement of luminal drug concentrations (18, 19). The idea is to 212 
correlate the directly measured drug concentration in the human gastrointestinal (GI) 213 
regions and the plasma drug concentration along with the drug dissolution in different GI 214 
tract by computational modeling. Results indicated that in vivo dissolution of MR 215 
mesalamine oral dosage forms were highly variable.  Pentasa released mesalamine 216 
throughout the GI tract including the stomach, while Apriso released mesalamine between 217 
duodenum and jejunum regions.  However, Lialda rarely released any mesalamine in first 7 218 
hrs.  Those MR formulations exhibited the different drug release profiles in vivo and in 219 
vitro.  However, the large amount of unmetabolized drugs was observed in feces, 220 
suggesting unreleased and/or undissolved.  In ibuprofen studies, high concentration of 221 
ibuprofen was observed in the stomach and small intestine at 7 hrs after oral administration 222 
(18).  With the elevation of gastric pH by the intake of liquid meal (Pulmocare®), higher 223 
drug concentration of ibuprofen in the stomach was observed (19).  However, the lower 224 
Cmax and delayed Tmax in the plasma profiles in the fed state were observed compared to 225 
ones in the fasted state suggesting the slower gastric emptying time in the fed state.  226 
Overall, the challenges are the limited data of in vivo dissolution in the different GI sites to 227 
validate the in vitro dissolution models and in silico simulation.  It would be a mutually 228 
beneficial if the industry, academia and the regulators to collaborate to produce and share 229 
more in vivo dissolution data. 230 
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Interpreting Drug Concentration Profiles in Plasma and Relating Them to In Vitro 231 
Dissolution Measurements/In Silico Predictions 232 
Dr. Marival Bermejo (Universidad Miguel Hernández de Elche) presented the exploratory 233 
data analysis of a human intubation study with the administration of an immediate release 234 
(IR) ibuprofen (weak acid) oral formulation. The specialized manometric catheter with 4 235 
sampling ports allowed the measurement of luminal drug concentrations, pH values as well 236 
as intestinal wall motility (19). Results indicated that ibuprofen in vivo dissolution depends 237 
on luminal pH (7). Additionally, time to the next Phase III wave post dose (TMMC) 238 
determined the arrival of most of the ibuprofen dose to the small intestine, consequently 239 
longer TMMC is reflected in lower Cmax and longer Tmax. Absorption rates estimated from 240 
plasma levels by deconvolution showed a good correlation with in vivo dissolution i.e. 241 
maximal absorption rates corresponded with the maximal ibuprofen concentrations in 242 
intestinal lumen. A compartmental (stomach-duodenum-jejunum-plasma) mass transport 243 
analysis incorporating TMMC, and pH-dependent dissolution reproduced closely the 244 
individual plasma levels and the inter-subject variability. These results confirmed the direct 245 
link between intestinal dissolution, luminal solution concentration and systemic absorption 246 
thus the impact of gastrointestinal variables as pH and motility in oral absorption. iPD 247 
methodologies incorporating these variables in combination with mass transport 248 
computational methods are necessary tools to optimize formulation development. 249 
 250 
iPD Methodologies – Future 251 
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Dr. Gordon L. Amidon (University of Michigan) presented his vision of in vivo predictive 252 
dissolution (iPD) to the future of Biopharmaceutics and to the implications of oral product 253 
development through the evolution of regulations on oral drug products, dissolution 254 
methodologies, and technologies to advance the understanding of the human GI physiologies. 255 
The improved understanding of complexed human GI physiology and the advancement of 256 
technologies allows us to develop the in vitro dissolution apparatuses, which are 257 
physiologically relevant to the human GI conditions, and the simulation and physiologically 258 
based pharmacokinetics modeling for the prediction of in vivo dissolution and drug 259 
absorption of oral dosage forms. Those movements have revolutionized and will keep 260 
advancing the development of drug products, the design of oral drug products, and the 261 
bioequivalent (BE) studies.  However, the regulatory agencies, academia, and industries 262 
should fully collaborate to facilitate this advancement and to validate in vitro models and to 263 
share limited amount of human permeability and plasma data.  The global harmonization will 264 
be necessary to promote science based dissolution methodologies and BE standards.  265 
 266 
Day 2 267 
A Two-Phase Dissolution-Partition Test for Characterizing BCS II Drugs Products 268 
and Establishing IVIVR 269 
Dr. Ping Gao (AbbVie) presented his work in developing a two-phase dissolution-partition 270 
test for evaluation of BCS II drug formulations.  This method, referred as to the biphasic 271 
test, permits dissolution in the aqueous media (with pH alteration) under a non-sink 272 
condition and simultaneous partition of the dissolved drug into an organic phase that acts as 273 
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an “absorption compartment”.  The partition of the drug into the organic phase is driven by 274 
the free drug concentration in the aqueous phase and this is to mimic absorption in 275 
vivo.  The theoretical model of the biphasic system was developed to reveal that the 276 
physiological relevance of this test method is based on the in vitro partitioning rate 277 
coefficient, kp, approximates the in vivo absorption rate coefficient, ka (20). Three case 278 
studies of BCS II drug formulations including ABT-072 (weak acid) (21), ritonavir (weak 279 
base) (22), and fenofibrate (23) were reviewed.  Their in vitro profiles obtained in 280 
biorelevant media under the optimal hydrodynamic condition by the biphasic test are 281 
closely correlated with relative exposures of these drugs in human subjects.  These cases 282 
jointly reveal the significant impact of supersaturation upon oral exposure of BCS II drugs 283 
and a complex interplay among the dissolution, precipitation, and partition processes that 284 
dictates the oral exposure. 285 
 286 
BCS IIb Drug Substances in the Gastro-Intestinal Simulator (GIS) 287 
Dr. Yasuhiro Tsume (University of Michigan) presented his work in developing a multi-288 
compartment transfer system, gastrointestinal simulator (GIS), to evaluate the 289 
bioperformance of weakly base drugs, ketoconazole and dasatinib as model drugs (24, 290 
25).  The GIS, which consists of three chambers, gastric, duodenal, and jejunal 291 
compartments with secretion chambers to supply appropriate media back into the gastric 292 
and duodenal chambers (26).  Using the GIS, Dr. Tsume demonstrated the occurrence of 293 
supersaturation and precipitation of BCS class IIb drugs and the enhanced absorption 294 
resulting from supersaturation effects by the combination study of infusion study and the 295 
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dissolution study and the potential to predict clinical outcome with in vitro dissolution 296 
methods (24, 25).  Dr. Tsume mentioned the importance of experimental conditions like 297 
aqueous volume (volume to the dose), buffer species, buffer capacity, buffer pH and gastric 298 
motility (gastric emptying rate and transit time) with experimental examples (27-30).  He 299 
also demonstrated the presence of absorption phase (biphasic setting) would be useful in 300 
the dissolution methodologies for certain drugs for more accurate in vivo prediction (31).   301 
 302 
Multicompartment Transfer Model to Predict Dissolution/Precipitation of Weakly Basic 303 
Drug 304 
Sanjaykumar Patel and Wei Zhu (Merck & Co., Inc., Kenilworth, NJ, USA) presented their 305 
work in developing a multi-compartment transfer system for evaluation of dissolution and 306 
precipitation of weakly basic drugs during the transfer out of the stomach into the 307 
intestine.  This transfer system includes a “gastric” compartment, an “intestinal” 308 
compartment, a “sink” compartment for removal of the drugs from intestinal compartment, 309 
and a “reservoir” compartment to re-supply FaSSIF media during the course of the 310 
experiment.  An in silico model was built to simulate the time-dependent dissolution and 311 
precipitation processes when drugs/formulations were tested using the transfer system, and 312 
the precipitation rate obtained from the model was used as the inputs for subsequent 313 
absorption modeling. Two case studies, dypyridamole and ketoconazole, were reviewed, as 314 
the in vitro dissolution and precipitation of these two drugs were analyzed using both 315 
transfer system and traditional two-stage dissolution. Using the fitted precipitation rate 316 
from transfer system as the inputs for GastroplusTM modeling, the predicted 317 
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pharmacokinetic profiles of orally dosed IR formulations were generally in agreement with 318 
observed clinical data. A sensitivity analysis on in vivo precipitation in GastroplusTM 319 
suggested an optimal prediction accuracy when precipitation rates from the transfer system 320 
was utilized. These case examples showed promising results to support this integrated in 321 
vitro/in silico transfer system as an alternative approach to estimate in vivo precipitation in 322 
intestinal compartment, which is one of the critical attributes for prediction of clinical 323 
bioperformance for weak basic compounds. 324 
BCS II/IV Drug Substances in the Artificial Stomach Duodenum (ASD) System  325 
Dr. David C. Sperry (Eli Lilly and Company) presented his work in artificial stomach and 326 
duodenum (ASD) as a tool to develop oral drug products.  This dissolution apparatus, 327 
which mimics the dynamic conditions of the human GI tract, helps predict the in vivo 328 
impact of oral dosage forms properties such as salts, solid forms, formulation composition, 329 
and particle size.  The goal of this approach is to reduce the number of animal studies 330 
required during formulation development while selecting the best possible oral dosage 331 
forms for clinical studies.  Certain drugs would supersaturate, precipitate, and/or dissolve in 332 
the duodenal region, which have impact on their absorption.  Those molecule/formulation 333 
related phenomena can be captured by ASD, which mimics the dynamic GI conditions, to 334 
support the in vivo prediction.  The drug concentration in the duodenal chamber of ASD 335 
can be predicted based on the drug concentration in the gastric chamber of ASD.  The 336 
difference between experimental results and calculated/expected results indicates additional 337 
dissolution and/or precipitation, which will provide tremendous helps to understand the in 338 
vivo dissolution and the potential problems of test drug/formulation.  Dr. Sperry presented a 339 
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few case studies with the different API forms (free base form vs. salt form), the different 340 
dosage strengths (low vs. high), the different pH and buffer viscosity to demonstrate the 341 
impact of in vivo dissolution of test oral formulations.  He demonstrated through those case 342 
studies that those in vitro dissolution profiles obtained with ASD combination of in silico 343 
absorption model, gCOAS, predict better in vivo performance and, hence, the usefulness 344 
and practicality of in vivo predictive dissolution methodology, ASD. 345 
 346 
Implementing In Vitro Dissolution Data into PBPK Models for Evaluation of Absorption 347 
from the Lower Intestine 348 
Dr. Maria Vertzoni (National and Kapodistrian University of Athens) presented the impact 349 
of absorption from the lower intestine on plasma pharmacokinetic profile. After oral 350 
administration of a drug product, the drug absorption from the lower intestine was of 351 
particular interest when considering the development of modified release products. It could 352 
also be useful, for understanding the pharmacokinetic performance of poorly soluble active 353 
pharmaceutical ingredients (APIs), BCS Class II and Class IV APIs, when those are 354 
administered in immediate release products and their drug absorption is incomplete in the 355 
upper intestine. For the evaluation of colonic absorption, knowledge of drug solubility and 356 
dissolution rates in the region is required but relevant estimations remain problematic, due to 357 
limited information on the conditions prevailing in the lower intestine. In recent years our 358 
understanding on the environment in the lower intestine has been increased (32, 33).  359 
Dr Vertzoni presented the usefulness of biorelevant in vitro data in PBPK models describing 360 
oral absorption from upper / middle as well as from lower intestine with various case 361 
examples.  362 
She presented the media simulating the contents of lower intestine i.e. distal ileum and 363 
proximal colon under conditions simulating the bioavailability and bioequivalence studies in 364 
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the fasted and in the fed states and a recently developed in vitro two-stage single-365 
compartment models for evaluating dissolution characteristics in the lower intestine. This 366 
approach evaluates the impact of dilution of ileal contents as they empty into the proximal 367 
colon and the potential precipitation of weak acids, due to the decrease of the pH in the 368 
proximal colon, particularly apparent in the fed state (34-36). To evaluate the importance of 369 
specific luminal characteristics within a specific region of intestinal lumen two levels of 370 
simulation of luminal composition were considered. Level I biorelevant media reflect luminal 371 
pH and buffer capacity whereas Level II biorelevant media take additionally into account 372 
luminal bile components and osmolality (35, 36). In addition, the importance of solid 373 
particles [i.e. of Level III simulation] was evaluated (36). For the evaluation of the impact of 374 
passive absorption from the lower intestine on the overall absorption process, in vitro 375 
dissolution data collected under conditions simulating the environment in the upper 376 
gastrointestinal lumen and under the conditions simulating the environment in the lower 377 
intestinal lumen were coupled with physiologically based oral absorption modelling to 378 
simulate the overall drug absorption process.  379 
Based on data collected using high dose low solubility APIs and a colon targeting product, 380 
dissolution characteristics in the lower intestine can be much different from that in upper 381 
intestine with potential impact on PBPK modelling.  382 
Dr Vertzoni concluded that in situations where stress effects are not expected to be of an 383 
issue (e.g. for immediate release products, pellets, products coated with pH sensitive 384 
polymers) Level II or even Level I (if API is not very lipophilic) biorelevant media in 385 
conjunction with the proposed two-stage in vitro methodology seem to be adequate for the 386 
evaluation of dissolution in the lower intestine. 387 
In Vivo Predictive Models for Oral Drug Absorption 388 
Dr. Nikoletta Fotaki (University of Bath, UK) discussed the use of biorelevant in vitro data 389 
within a physiologically-based pharmacokinetic (PBPK) model environment for the 390 
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prediction of in vivo performance with a focus on the points to be considered and the 391 
challenges regarding the type of in vivo predictive data needed. Due to the pharmacokinetic 392 
reasons for attrition in drug development the need for in vivo predictive in vitro tests and 393 
the increased use of absorption modeling during drug development are evident (37). The 394 
first aspects discussed related to the methodology of in vivo predictive solubility and 395 
dissolution studies in terms of 1) the appropriate medium to be used (buffers, 396 
pharmacopoeia media, biorelevant media), 2) the continuous update of the biorelevant 397 
media based on physiological data (i.e. FaSSIF V1/ V2/ V3) and 3) the type of in vitro 398 
dissolution apparatus to be used (USP dissolution apparatus I-IV and other approaches such 399 
as Dissolution Stress Test Device, TNO Intestinal Models). A case study in which a 400 
successful IVIVC for an immediate and a prolonged release formulation of a BCS Class II 401 
compound was achieved based on appropriate selection of in vitro conditions (media, 402 
apparatus) in combination with PBPK modeling was presented. The impact of in vitro 403 
hydrodynamics on the development of in vitro-in vivo correlations for modified release 404 
formulations of a BCS Class II compound, were discussed in the second case study (38). It 405 
was shown that the hydrodynamics of USP apparatus II, III and IV may all be adequate as a 406 
starting point for generating IVIVCs of up to 7 mm monolithic dosage forms with low drug 407 
load, at least in the fasted state. The next point discussed related to the need of appropriate 408 
in vivo predictive enzyme and transporter data apart from the solubility/ dissolution data in 409 
the PBPK models. The third case study involved the development of a successful IVIVC 410 
for an amorphous sustained release formulation of a BCS Class II compound based on 411 
appropriate selection of in vitro conditions (media, apparatus) and enzyme/transporter data 412 
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in combination with PBPK modeling. In the cases that the compound undergoes in vivo 413 
degradation, biorelevant in vitro degradation data has to be generated and used as an input 414 
in the PBPK model. This was revealed through the fourth case study in which the 415 
development of a successful IVIVC for an amorphous formulation of a BCS Class II 416 
compound based on appropriate selection of in vitro conditions (media, apparatus) and in 417 
vitro degradation data in combination with PBPK modeling was shown. In the last part of 418 
her presentation she elaborated on the characterization of the dissolution of other 419 
components of the formulation apart from the API, such as functional excipients or co-420 
formers in co-crystals that can play a vital role in the assessment of bioavailability (39, 40) 421 
 422 
Physiologically Based Pharmacokinetic Simulations Integrating In Vitro Dissolution 423 
Results for Preclinical and Clinical Formulation Development 424 
Dr. Neil Parrott (F Hoffmann LaRoche) presented a pharmaceutical industry perspective on 425 
the utility of physiologically based absorption models integrating biorelevant in vitro 426 
dissolution data to guide formulation development.  Within Roche, absorption modeling 427 
plays a key role in biopharmaceutics sub-teams which are formed to address formulation 428 
challenges in a project. The sub-teams bring together expertise in drug metabolism and 429 
pharmacokinetics, clinical pharmacology and formulation and the models provides an 430 
invaluable platform for integration of data, hypothesis generation and extrapolation. This is 431 
illustrated with 2 case studies.  The first shows how an oral absorption model, developed in 432 
GastroPlus™, can be verified with Phase 1 data for immediate-release capsules and then 433 
applied to understand drug release from Phase 2 tablets and granules and to develop an in 434 
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vitro-in vivo correlation (IVIVC) model with biorelevant USP2 dissolution data and the 435 
mechanistic absorption model (41).  The second example covers the application of 436 
physiologically based absorption modeling during the late stage clinical development and 437 
filing of Alectinib (42).  The modelling helped to predict and understand the impact of food 438 
and gastric pH changes on Alectinib absorption. 439 
The Impact of In Vivo Predictive Dissolution on Generic Drug Development and Review 440 
Dr. Robert Lionberger (Food and Drug Administration, USA) presented that in vivo 441 
predictive dissolution (IVPD) could have its highest impact on generic drugs and be a path 442 
to expand access to generic competition. Many generic products are in small markets where 443 
the cost of an in vivo bioequivalence study could be a significant barrier to entry. This is an 444 
opportunity for IVPD to make a positive public health impact by supporting efficient in 445 
vitro bioequivalence standards. FDA has guidance that provides for BCS biowaivers for 446 
class 1 and 3 drug products, but BCS class 2 and 4 are where IVPD is the critical step. 447 
IVPD needs to be linked closely with modeling and simulation of drug absorption and 448 
distribution to fully characterize risks of bioavailability or bioequivalence differences. 449 
Between 2013 and 2017 under GDUFA I, FDA has support a wide variety of research to 450 
close some of the scientific gaps related to bioequivalence. As we move in to GDUFA II, it 451 
is time to move toward implementation of IVPD for generic drugs. 452 
 453 
Future improvement and direction 454 
In order to understand the bioperformance of the drug substance and product of interest, 455 
great progresses have been made in recent years.  Scientists have been developing and 456 
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conducting science-centric researches to advance the area of in vivo prediction.   Many 457 
scientists agreed that in vivo predictive dissolutions and computational approaches would 458 
be the right direction and the future to improve the oral drug dosage forms and to predict in 459 
vivo plasma profiles.  The development of decision tree to select an appropriate dissolution 460 
methodology and experimental conditions for the test API formulation was extensively 461 
discussed to direct the formulation and analytical scientists and to harmonize the in vitro 462 
dissolution methodologies based on BCS and physicochemical properties.  However, there 463 
is no clear answer for the selection of one methodology over the other methodologies.  464 
Thus, the different dissolution and simulation methodologies can be offered to scientists 465 
and regulatory agents as a toolbox and they can freely select the methodologies for their 466 
purposes.   467 
Two important questions are: 1) if the scientific community can cross-validate their own 468 
experimental/computational methodologies and/or harmonize their experimental 469 
methodologies so that the results and agreements/disagreements could be discussed on the 470 
same ground, and 2) if the scientific community and the regulatory community can develop 471 
the field of new in vitro dissolution methodologies for bioequivalence and in vivo 472 
predictive dissolution and harmonize the common ground.  Academia, industry and 473 
regulators should collaborate to derive the maximum benefit from in vivo predictive 474 
dissolution and computational applications.  It would be mutual benefit to all to expand our 475 
knowledge and advance this area of sciences.   476 
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